@Article{Rakowska2023,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="110",
number="2",
year="2023",
title="Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment",
abstract="The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata Scale (AAS). In mild alopecia areata, very ultra-high potency topical glucocorticoids and intralesional triamcinolone acetonide are the mainstay of treatment. In moderate to severe alopecia areata, systemic treatment is usually required. Currently, the only drug dedicated for alopecia areata, approved in Europe and the United States is baricitinib. Ritlecitinib, a JAK3/TEC inhibitor is approved in the United States for individuals 12 years of age and older with severe alopecia areata and is expected to be approved in Europe soon. Other systemic medications used in alopecia areata include glucocorticoids, cyclosporine, and methotrexate. Contact immunotherapy may be considered. In alopecia areata, long-maintenance treatment is of substantial significance.",
author="Rakowska, Adriana
and Rudnicka, Lidia
and Olszewska, Małgorzata
and Bergler-Czop, Beata
and Czuwara, Joanna
and Brzezińska-Wcisło, Ligia
and Narbutt, Joanna
and Placek, Waldemar
and Zegarska, Barbara",
pages="101--120",
doi="10.5114/dr.2023.127705",
url="http://dx.doi.org/10.5114/dr.2023.127705"
}